ISRCTN58806684 https://doi.org/10.1186/ISRCTN58806684

GnRH antagonist administration for patients at high risk of severe Ovarian Hyperstimulation Syndrome (OHSS) down regulated GnRH agonist

Submission date 14/12/2005	**Recruitment status** No longer recruiting
Registration date 28/02/2006	**Overall study status** Completed
Last Edited 24/08/2009	**Condition category** Urological and Genital Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Mohamed Aboulghar

Contact details
3, Street 161
Hadayek El Maadi
Cairo
Egypt
11431
+20 2525 4944
ghar@link.net

Additional identifiers

Study information

Scientific Title

Study objectives

Gonadotropin-Releasing Hormone (GnRH) antagonist has a direct impact on granulosa cells reducing estradiol (E2) production, thus may reduce incidence of severe OHSS

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved by the Institutional review board, August 2005

Study design
Prospective randomised controlled trial

Primary study design
Interventional

Study type(s)
Prevention

Health condition(s) or problem(s) studied
Ovarian Hyperstimulation Syndrome (OHSS)

Interventions
GnRH antagonist versus coasting (care as usual)

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
GnRH antagonist

Primary outcome(s)
Current information as of 24/08/09:
High quality embryos

Initial information at time of registration:
OHSS

Key secondary outcome(s))
Current information as of 24/08/09:
1. Days of intervention
2. Number of oocytes
3. Pregnancy rate
4. Number of cryopreserved embryos
5. Incidence of severe OHSS

Initial information at time of registration:
Pregnancy rate

Completion date
01/06/2006

Eligibility

Key inclusion criteria
Women undergoing in vitro fertilisation (IVF) or IntraCytoplasmic Sperm Injection (ICSI) trial down regulated with GnRH agonist and at risk of severe OHSS

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
Female

Key exclusion criteria
1. Women above 39 years old
2. Medical illness

Date of first enrolment
30/11/2005

Date of final enrolment
01/06/2006

Locations

Countries of recruitment
Egypt

Study participating centre
3, Street 161
Cairo
Egypt
11431

Sponsor information

Organisation
The Egyptian IVF-ET Centre (Egypt)

ROR
https://ror.org/035aahr55

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
The Egyptian IVF-ET center

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2007		Yes	No